Laahn H. Foster

Hematology
1215 Lee St
Charlottesville, VA 22908

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications

MRD in multiple myeloma: Moving from "minimal" to "measurable".

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Journal: Blood reviews
Published: March 24, 2026

Staging FDG PET/CT prediction of bone marrow involvement by diffuse large B-cell lymphoma leading to delayed recognition of multiple myeloma.

Staging FDG PET/CT prediction of bone marrow involvement by diffuse large B-cell lymphoma leading to delayed recognition of multiple myeloma.

Journal: Journal of hematopathology
Published: September 14, 2025

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses.

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses.

Journal: Blood cancer journal
Published: June 06, 2025

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.

Journal: Blood
Published: August 01, 2024

Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs.

Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs.

Journal: Expert opinion on biological therapy
Published: May 14, 2019

The role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas.

The role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas.

Journal: Current treatment options in oncology
Published: May 16, 2015
Showing 1-6 of 6

Last Updated: 09/26/2026